Correlation Between Neurobo Pharmaceuticals and Allarity Therapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Neurobo Pharmaceuticals and Allarity Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Neurobo Pharmaceuticals and Allarity Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Neurobo Pharmaceuticals and Allarity Therapeutics, you can compare the effects of market volatilities on Neurobo Pharmaceuticals and Allarity Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Neurobo Pharmaceuticals with a short position of Allarity Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Neurobo Pharmaceuticals and Allarity Therapeutics.

Diversification Opportunities for Neurobo Pharmaceuticals and Allarity Therapeutics

0.81
  Correlation Coefficient

Very poor diversification

The 3 months correlation between Neurobo and Allarity is 0.81. Overlapping area represents the amount of risk that can be diversified away by holding Neurobo Pharmaceuticals and Allarity Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Allarity Therapeutics and Neurobo Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Neurobo Pharmaceuticals are associated (or correlated) with Allarity Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Allarity Therapeutics has no effect on the direction of Neurobo Pharmaceuticals i.e., Neurobo Pharmaceuticals and Allarity Therapeutics go up and down completely randomly.

Pair Corralation between Neurobo Pharmaceuticals and Allarity Therapeutics

Given the investment horizon of 90 days Neurobo Pharmaceuticals is expected to generate 1.13 times more return on investment than Allarity Therapeutics. However, Neurobo Pharmaceuticals is 1.13 times more volatile than Allarity Therapeutics. It trades about -0.16 of its potential returns per unit of risk. Allarity Therapeutics is currently generating about -0.18 per unit of risk. If you would invest  285.00  in Neurobo Pharmaceuticals on August 28, 2024 and sell it today you would lose (43.00) from holding Neurobo Pharmaceuticals or give up 15.09% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthStrong
Accuracy100.0%
ValuesDaily Returns

Neurobo Pharmaceuticals  vs.  Allarity Therapeutics

 Performance 
       Timeline  
Neurobo Pharmaceuticals 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Neurobo Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's fundamental drivers remain very healthy which may send shares a bit higher in December 2024. The recent disarray may also be a sign of long period up-swing for the firm investors.
Allarity Therapeutics 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Allarity Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Even with weak performance in the last few months, the Stock's essential indicators remain relatively invariable which may send shares a bit higher in December 2024. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors.

Neurobo Pharmaceuticals and Allarity Therapeutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Neurobo Pharmaceuticals and Allarity Therapeutics

The main advantage of trading using opposite Neurobo Pharmaceuticals and Allarity Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Neurobo Pharmaceuticals position performs unexpectedly, Allarity Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Allarity Therapeutics will offset losses from the drop in Allarity Therapeutics' long position.
The idea behind Neurobo Pharmaceuticals and Allarity Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.

Other Complementary Tools

Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Commodity Directory
Find actively traded commodities issued by global exchanges
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities